Baird lowered the firm’s price target on Dentsply Sirona (XRAY) to $12 from $14 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona initiated with an Underweight at Barclays
- DENTSPLY SIRONA Appoints Interim CFO Michael Pomeroy
- Dentsply Sirona price target lowered to $14 from $18 at Barrington
- Dentsply Sirona price target lowered to $12 from $14 at Morgan Stanley
- Dentsply Sirona price target lowered to $13 from $16 at Mizuho